US imposes 100% tariff on imported patented pharmaceuticals, impacting Australian exporters
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals manufactured outside the US, targeting Australia’s $US1.32 billion annual drug exports, primarily from CSL. The tariff, enacted under Section 232 of the Trade Expansion Act, excludes generic drugs and offers reduced rates (20% or zero) for companies relocating production to the US or negotiating favorable drug pricing deals. Australia’s largest exporter, CSL, benefits from exemptions for plasma-derived therapies and existing US manufacturing, but smaller firms face uncertainty. The move reflects Trump’s push to re-shore drug production amid national security concerns, though it risks escalating trade tensions. Australian officials, including Health Minister Mark Butler, have vowed not to alter the country’s Pharmaceutical Benefits Scheme to appease US demands, while opposition leader Angus Taylor pledged to advocate for exemptions. Other countries like the EU, Japan, and the UK secured lower tariff rates through trade deals, highlighting Australia’s lack of a preferential arrangement. The tariff’s implementation follows a Supreme Court ruling invalidating Trump’s broader ‘Liberation Day’ tariffs, but this measure remains unaffected due to its legal basis.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented drugs manufactured outside the US on June 2025 (Washington time).
- Australia exported approximately $US1.32 billion (or $US1.91 billion in 2024) worth of pharmaceuticals to the US in 2024/2025, per UN COMTRADE data.
- CSL (ASX-listed biotech firm) is Australia’s largest pharmaceutical exporter to the US, with significant manufacturing operations in the US (Illinois, North Carolina) and Australia.
- The tariff applies only to patented drugs, not generic medicines.
- Companies moving production to the US can reduce tariffs to 20%, and tariffs drop to zero if the US achieves 'most favoured nation' drug pricing status from the exporting country.
- Japan, EU, South Korea, Switzerland, and Liechtenstein received 15% tariff rates, while the UK secured a 10% rate (with potential for zero).
- CSL’s plasma-derived therapies (majority of its US exports) may be exempt if they meet an urgent US health need or come from countries with a US trade deal.
- CSL announced a $US1.5 billion ($2.17 billion AUD) expansion of its Illinois facility in 2024, with completion set for 2031.
- Large pharmaceutical companies have 120 days to announce re-shoring plans to reduce tariffs to 20%, while smaller firms have 180 days.
- The tariff is enacted under Section 232 of the Trade Expansion Act (not presidential emergency powers), so it is unaffected by the February 2025 Supreme Court ruling striking down Trump’s ‘Liberation Day’ tariffs.
- Health Minister Mark Butler stated Australia would not negotiate changes to the Pharmaceutical Benefits Scheme (PBS) due to its 80-year success in keeping prices affordable.
- Opposition Leader Angus Taylor (Coalition) expressed concern and pledged to work with the government to overturn or exempt Australian exporters from the tariffs.
Points of Difference
Details reported by only one source:
- The White House official explicitly stated 'Australia does not have a special pharma tariff rate' despite being a close ally.
- The tariff adjustment for steel-containing products was mentioned: if a product has less than 15% steel, the additional tariff drops to zero; if over 15%, the steel tariff becomes 25% of the total product value.
- The tariff announcement was timed to mark one year since Trump’s ‘Liberation Day’ tariffs (February 2025).
- The Commerce Department has discretion to grant exemptions to companies like CSL after they submit their re-shoring plans.
- Medicines Australia stated that 'most favoured nation' rules are already hampering imports to Australia, with new medicines launches being scrutinized due to low Australian prices.
- The tariff was invoked under national security powers, with Trump’s executive order citing 'threatened impairment of the national security' from pharmaceutical imports.
- AstraZeneca was mentioned as a company that had already struck specific deals with the White House to avoid tariffs.
- A senior administration official stated that 'too many drugs driven by R&D in the US are now produced abroad,' emphasizing the need for domestic production.
- The ABC reported that Trump previously suggested the tariff could be as high as 200% in July 2024.
- The ABC highlighted that CSL had been investing in US manufacturing to circumvent the tariff, with a social media post from Trump in September 2024 suggesting the tariff would take effect from October 2024.
- Communications Minister Anika Wells stated the Australian PBS is 'world leading' and 'not for sale,' emphasizing its high value to Australians.
- The Guardian noted that the tariff decision was 'disappointing' but reiterated Australia’s commitment to the PBS.
- The Guardian mentioned that the tariff would apply to 'branded pharmaceuticals' imported into the US, not just all patented drugs.
- Health Minister Mark Butler called the decision 'deeply disappointing and deeply concerning' in SBS’s headline.
- The SMH repeated the same details as THEAGE regarding the tariff’s application to Australian drugs and caveats for CSL, with no additional unique information.
Contradictions
Conflicting information between sources:
- The ABC reported Trump previously suggested the tariff could be as high as 200%, but no other source mentioned this specific figure or context.
- The Guardian stated the tariff applies to 'branded pharmaceuticals,' while THEAGE and ABC described it as applying to 'patented drugs'—no source clarifies if these terms are interchangeable.
- The NEWSCOMAU mentioned that the tariff was invoked under national security powers, but THEAGE and ABC did not emphasize this justification in their summaries.
- The ABC reported CSL did not expect material impact from the tariff in September 2024, but THEAGE and GUARDIAN noted CSL’s recent $US1.5 billion expansion in the US as a response to the tariff threat.
- The NEWSCOMAU stated that 'most favoured nation' rules are already impacting Australian imports, but no other source provided evidence or quotes from pharmaceutical companies confirming this.
Source Articles
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....